Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Pyrazoles
  • Pyrimidines

abstract

  • Ibrutinib, as compared with ofatumumab, significantly improved progression-free survival, overall survival, and response rate among patients with previously treated CLL or SLL. (Funded by Pharmacyclics and Janssen; RESONATE ClinicalTrials.gov number, NCT01578707.).

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4134521

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1400376

PubMed ID

  • 24881631

Additional Document Info

start page

  • 213

end page

  • 23

volume

  • 371

number

  • 3